AzTrials
AzTrials

Rheumatoid ArthritisPhase 2/3SELECTSUNRISENCT02720523

A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs

A Phase 2/3 study testing Upadacitinib in people with Rheumatoid Arthritis, run by AbbVie at 50 sites in Japan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a randomized, double-blind study comparing ABT-494 to placebo in Japanese participants with moderately to severely active rheumatoid arthritis who are on a stable dose of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and have an inadequate response. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Rheumatoid Arthritis
What is being tested?
Upadacitinib
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
197 participants
Where
50 sitesJapan
Study dates
22 Mar 2016to 7 Jun 2022
Phase
Phase 2/3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosis of rheumatoid arthritis (RA) for >= 3 months who also fulfill the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for RA.
  • Subjects have been receiving conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) therapy >= 3 months and on a stable dose for >= 4 weeks prior to the first dose of study drug.
  • Subject has >= 6 swollen joints (based on 66 joint counts) and >= 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits.
  • Subjects with prior exposure to at most one biological disease-modifying anti-rheumatic drug (bDMARD) may be enrolled (up to 20% of total number of subjects) after the required washout period. Specifically, prior to enrollment:
  • Subjects with limited exposure to bDMARD (< 3 months) OR
  • Subjects who are responding to bDMARD therapy but had to discontinue due to intolerability (regardless of treatment duration).

Who cannot join

  • Prior exposure to any Janus kinase (JAK) inhibitor
  • Subjects who are considered inadequate responders (lack of efficacy) to bDMARD therapy, after minimum 3 months treatment, as determined by the Investigator.
  • History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than RA (including but not limited to gout, systemic lupus erythematosus, psoriatic arthritis, axial spondyloarthritis [SpA] including ankylosing spondylitis and non-radiographic axial SpA, reactive arthritis, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, fibromyalgia [currently with active symptoms]). Current diagnosis of secondary Sjogren's Syndrome is permitted.

Trial locations and contacts

50 sites in 1 country.

50 sites in 1 country

Japan50 sites
  • National Hospital Organization Asahikawa Medical Center /ID# 147994

    Asahikawa, Hokkaido, 070-8644

  • Katayama Orthopedic Rheumatology Clinic /ID# 147976

    Asahikawa, Hokkaido, 078-8243

  • NHO Chiba-East-Hospital /ID# 147996

    Chiba, 260-8712

  • St.Luke's International Hospital /ID# 147969

    Chuo-ku, Tokyo, 104-8560

  • Sugimoto Rheumatology and Internal Medicine Clinic /ID# 147989

    Fukui, 910-0068

  • Hamanomachi Hospital /ID# 147991

    Fukuoka, Fukuoka, 810-8539

  • Kyushu University Hospital /ID# 148008

    Fukuoka, Fukuoka, 812-8582

  • Hopsital of the University of Occupational and Enviromental Health /ID# 147970

    Fukuoka, 8078556

  • Shono Rheumatism Clinic /ID# 147971

    Fukuoka, 814-0002

  • Hiroshima Rheumatology Clinic /ID# 147981

    Hiroshima, 730-0017

  • Ichinomiya Municipal Hospital /ID# 147992

    Ichinomiya-shi, Tokyo, 491-8558

  • Matsubara Mayflower Hospital /ID# 147967

    Katō, 673-1462

  • Saitama Medical Center, Saitama Medical University /ID# 147965

    Kawagoe-shi, Saitama, 350-8550

  • Kumamoto Orthopaedic Hospital /ID# 147972

    Kumamoto, Kumamoto, 862-0976

  • Kumamoto Rheumatology Clinic /ID# 147988

    Kumamoto, 861-5515

  • St. Mary's Hospital /ID# 147979

    Kurume, 830-8543

  • Kagawa University Hospital /ID# 148001

    Kyoto, 615-8256

  • Marunouchi Hospital /ID# 147973

    Matsumoto, 390-0841

  • Toho University Ohashi Medical Center /ID# 148003

    Meguro-ku, Tokyo, 1538515

  • Yu Family Clinic /ID# 147990

    Miyagi, 981-0112

  • Medical Corporation Keiai Kai Clinic /ID# 147975

    Miyazaki, Miyazaki, 880-0053

  • Nagaoka Red Cross Hospital /ID# 147974

    Nagaoka-shi, Niigata, 940-2108

  • Nagoya University Hospital /ID# 148005

    Nagoya, Aichi-ken, 466-8560

  • JP Red Cross Nagoya Daiichi /ID# 147995

    Nagoya, 453-8511

  • Kondo Clinic for Ortho & Rheum /ID# 147984

    Nagoya, 464-0071

  • The Hospital of Hyogo College of Medicine /ID# 147978

    Nishinomiya-shi, Hyōgo, 663-8501

  • Oribe Clinic of Rheumatology and Internal Medicine /ID# 149308

    Ōita, 870-0823

  • Okayama City Gen Med Ctr /ID# 148000

    Okayama, 700-8557

  • Miyashita Rheumatology Clinic /ID# 147997

    Ōmura, 856-0836

  • NHO Osaka Minami Med Ctr /ID# 147986

    Osaka, Kawachinagano-shi, 586-8521

  • National Hospital Organization Sagamihara National Hospital /ID# 148221

    Sagamihara-shi, Kanagawa, 252-0315

  • Sagawa Akira Rheumatology Clin /ID# 147987

    Sapporo, 060-0001

  • Sapporo City General Hospital /ID# 147968

    Sapporo, 060-8604

  • Tohoku University Hospital /ID# 148435

    Sendai, Miyagi, 980-8574

  • Hikarigaoka Spellman Hospital /ID# 147993

    Sendai, 983-0833

  • Setagaya Rheumatic Clinic /ID# 148009

    Setagaya-ku, Tokyo, 156-0052

  • Niigata Rheumatic Center /ID# 148002

    Shibata-shi, Niigata, 957-0054

  • Tokito Clinic Rheumatology and Orthopaedics Surgery /ID# 147980

    Shimonoseki-shi, Yamaguchi, 752-0976

  • Jichi Medical University Hospital /ID# 148220

    Shimotsuke-shi, Tochigi, 329-0498

  • Keio University Hospital /ID# 147982

    Shinjuku-ku, Tokyo, 160-8582

  • Tokyo Women's Medical University Hospital /ID# 148007

    Shinjuku-ku, Tokyo, 162-8666

  • Medical Corporation Uchida Clinic /ID# 148219

    Sumida-ku, Tokyo, 130-0013

  • Honjo Rheumatism Clinic /ID# 147983

    Takaoka, 933-0874

  • Inoue Hospital /ID# 147966

    Takasaki, Gunma, 3700053

  • Takikawa Municipal Hospital /ID# 149309

    Takikawa, 073-0022

  • Juntendo University Hospital /ID# 147999

    Tokyo, 113-8431

  • National Hospital Organization Tokyo Medical Center /ID# 147998

    Tokyo, 152-8902

  • Nihon University Itabashi Hosp /ID# 147977

    Tokyo, 173-0032

  • Oki Medical Clinic /ID# 147985

    Tomakomai, 053-0018

  • Toneyama National Hospital /ID# 148006

    Toyonaka, 560-8552

Other trials in Japan

About this study

Official title: A Phase 2b/3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Japanese Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs

This is a randomized, double-blind study comparing ABT-494 to placebo in Japanese participants with moderately to severely active rheumatoid arthritis who are on a stable dose of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and have an inadequate response.

Following marketing approval of upadacitinib for rheumatoid arthritis in Japan, this study will become a post-marketing clinical study and include a long-term extension period.

Read the detailed description

This study consisted of a 35-day screening period; a 12-week randomized, double-blind, parallel-group, placebo-controlled treatment period (Period 1); a 248-week blinded long-term extension period (Period 2); and a 30-day follow-up period (call or visit).

Participants who met eligibility criteria were randomized in a 3:3:3:1:1:1 ratio to one of six treatment groups:

  • Group 1: Upadacitinib 7.5 mg QD (Period 1) → upadacitinib 7.5 mg QD (Period 2)
  • Group 2: Upadacitinib 15 mg QD (Period 1) → upadacitinib 15 mg QD (Period 2)
  • Group 3: Upadacitinib 30 mg QD (Period 1) → upadacitinib 30 mg QD (Period 2)
  • Group 4: Placebo (Period 1) → upadacitinib 7.5 mg QD (Period 2)
  • Group 5: Placebo (Period 1) → upadacitinib 15 mg QD (Period 2)
  • Group 6: Placebo (Period 1) → upadacitinib 30 mg QD (Period 2)
Being tested
Placebo, Upadacitinib
Keywords
rheumatoid arthritis, ABT-494, Japanese, Antirheumatic agents
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PlaceboDrug

    Tablet; Oral

  • UpadacitinibDrug

    Also called ABT-494, RINVOQ™

    Tablet; Oral

Study groups in NCT02720523
Study groupRoleWhat they receive
Placebo / Upadacitinib 7.5 mgExperimentalPeriod 1: Participants will receive placebo once daily for 12 weeks. Period 2: Participants will receive Upadacitinib 7.5 mg once daily for 248 weeks.
Receives: Drug: Placebo; Drug: Upadacitinib
Placebo / Upadacitinib 15 mgExperimentalPeriod 1: Participants will receive placebo once daily for 12 weeks. Period 2: Participants will receive upadacitinib 15 mg once daily for 248 weeks.
Receives: Drug: Placebo; Drug: Upadacitinib
Placebo / Upadacitinib 30 mgExperimentalPeriod 1: Participants will receive placebo once daily for 12 weeks. Period 2: Participants will receive upadacitinib 30 mg once daily until regulatory approval of RA indication in Japan at which point they will switch to receive upadacitinib 15 mg once daily. Participants will receive upadacitinib for 248 weeks.
Receives: Drug: Placebo; Drug: Upadacitinib
Upadacitinib 7.5 mg / Upadacitinib 7.5 mgExperimentalPeriod 1: Participants will receive upadacitinib 7.5 mg once daily for 12 weeks. Period 2: Participants will receive upadacitinib 7.5 mg once daily for 248 weeks.
Receives: Drug: Upadacitinib
Upadacitinib 15 mg / Upadacitinib 15 mgExperimentalPeriod 1: Participants will receive upadacitinib 15 mg once daily for 12 weeks. Period 2: Participants will receive upadacitinib 15 mg once daily for 248 weeks.
Receives: Drug: Upadacitinib
Upadacitinib 30 mg / Upadacitinib 30 mgExperimentalPeriod 1: Participants will receive upadacitinib 30 mg once daily for 12 weeks. Period 2: Participants will receive upadacitinib 30 mg once daily until regulatory approval of RA indication in Japan at which point they will switch to receive upadacitinib 15 mg once daily. Participants will receive upadacitinib for 248 weeks.
Receives: Drug: Upadacitinib

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12

    Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria:

    1. ≥ 20% improvement in 68-tender joint count;
    2. ≥ 20% improvement in 66-swollen joint count; and
    3. ≥ 20% improvement in at least 3 of the 5 following parameters:
    • Physician global assessment of disease activity
    • Patient global assessment of disease activity
    • Patient assessment of pain
    • Health Assessment Questionnaire - Disability Index (HAQ-DI)
    • High-sensitivity C-reactive protein (hsCRP).

    Measured: Baseline and Week 12

Secondary outcomes (11)
  1. Change From Baseline in Disease Activity Score 28 (DAS28) (CRP) at Week 12

    The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.

    Measured: Baseline and Week 12

  2. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 12

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability.

    A negative change from Baseline in the overall score indicates improvement.

    Measured: Baseline and Week 12

  3. Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12

    Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria:

    1. ≥ 50% improvement in 68-tender joint count;
    2. ≥ 50% improvement in 66-swollen joint count; and
    3. ≥ 50% improvement in at least 3 of the 5 following parameters:
    • Physician global assessment of disease activity
    • Patient global assessment of disease activity
    • Patient assessment of pain
    • Health Assessment Questionnaire - Disability Index (HAQ-DI)
    • High-sensitivity C-reactive protein (hsCRP).

    Measured: Baseline and Week 12

  4. Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12

    Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria:

    1. ≥ 70% improvement in 68-tender joint count;
    2. ≥ 70% improvement in 66-swollen joint count; and
    3. ≥ 70% improvement in at least 3 of the 5 following parameters:
    • Physician global assessment of disease activity
    • Patient global assessment of disease activity
    • Patient assessment of pain
    • Health Assessment Questionnaire - Disability Index (HAQ-DI)
    • High-sensitivity C-reactive protein (hsCRP).

    Measured: Baseline and Week 12

  5. Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12

    The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health).

    The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.

    Measured: Baseline and Week 12

  6. Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12

    Low disease activity. was defined as a DAS28 score less than or equal to 3.2. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.

    Measured: Week 12

  7. Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12

    Clinical remission was defined as a DAS28 (CRP) score less than 2.6. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.

    Measured: Week 12

  8. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1

    Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria:

    1. ≥ 20% improvement in 68-tender joint count;
    2. ≥ 20% improvement in 66-swollen joint count; and
    3. ≥ 20% improvement in at least 3 of the 5 following parameters:
    • Physician global assessment of disease activity
    • Patient global assessment of disease activity
    • Patient assessment of pain
    • Health Assessment Questionnaire - Disability Index (HAQ-DI)
    • High-sensitivity C-reactive protein (hsCRP).

    Measured: Baseline and Week 1

  9. Change From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) at Week 12

    The FACIT Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better quality of life. A positive change from Baseline indicates improvement.

    Measured: Baseline and Week 12

  10. Change From Baseline in Rheumatoid Arthritis Work Instability Scale (RA-WIS) at Week 12

    RA-WIS is a simple validated tool to evaluate work instability (the consequence of a mismatch between an individual's functional ability and their work tasks). RA-WIS consists of 23 questions relating to the participant's functioning in their work environment, each answered as Yes or No. The total score is the number of questions answered Yes, and ranges from 0 to 23.

    A score < 10 means low risk and no action is needed, scores between 10 and 17 indicate medium risk and appropriate advice and information should be given. If the score is > 17, it means high risk and it could warrant referral.

    A negative change from Baseline indicates improvement.

    Measured: Baseline and Week 12

  11. Change From Baseline in the Severity of Morning Stiffness at Week 12

    Morning stiffness severity was determined by the Patient's Assessment of Severity and Duration of Morning Stiffness questionnaire. Participants rated the severity of morning stiffness on awakening over the past 7 days on a scale from 0 (No morning stiffness) to 10 (Worst possible morning stiffness).

    Measured: Baseline and Week 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Mar 2016 (estimated)
  2. Study start22 Mar 2016
  3. Primary completion3 Aug 2017
  4. Study completion7 Jun 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
197 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02720523
Sponsor's protocol ID
M14-663
Acronym
SELECTSUNRISE
Status last verified
Jun 2023
First submitted
22 Mar 2016
Last updated
7 Jun 2023
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Publications

  • Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Zhou Y, Othman AA, Pangan AL, Kitamura S, Meerwein S, Tanaka Y. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. Rheumatology (Oxford). 2020 Nov 1;59(11):3303-3313. doi: 10.1093/rheumatology/keaa084.

    PubMed 32277824
  • Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Konishi Y, Chonan S, Ikeda K, Camp HS, Tanaka Y. Long-term safety and efficacy of upadacitinib in Japanese patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: 5-year results from the SELECT-SUNRISE randomised controlled trial. RMD Open. 2025 Nov 4;11(4):e006213. doi: 10.1136/rmdopen-2025-006213.

    PubMed 41193232
  • Yamaoka K, Tanaka Y, Kameda H, Khan N, Sasaki N, Harigai M, Song Y, Zhang Y, Takeuchi T. The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. Drug Saf. 2021 Jun;44(6):711-722. doi: 10.1007/s40264-021-01067-x. Epub 2021 May 27.

    PubMed 34041702
  • Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Yokoyama M, Pangan AL, Konishi Y, Meerwein S, Tanaka Y. Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). Arthritis Res Ther. 2021 Jan 6;23(1):9. doi: 10.1186/s13075-020-02387-6.

    PubMed 33407801

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing Upadacitinib in people with Rheumatoid Arthritis, run by AbbVie at 50 sites in Japan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 50 sites in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 21 Oct 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (time frame: Baseline and Week 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02720523, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jun 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in